Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -0.50% | 43.97 | 0.9% | $1186.44m | |
| ABBV | AbbVie, Inc. | -0.22% | 107.12 | 1.9% | $1023.77m | |
| JNJ | Johnson & Johnson | -0.23% | 164.48 | 0.7% | $988.09m | |
| MRK | Merck & Co., Inc. | 0.81% | 73.64 | 0.7% | $914.30m | |
| LLY | Eli Lilly & Co. | -0.26% | 231.58 | 1.1% | $588.95m | |
| BMY | Bristol-Myers Squibb Co. | -0.61% | 60.26 | 1.0% | $575.61m | |
| AZN | AstraZeneca Plc | 1.46% | 60.35 | 1.0% | $353.10m | |
| NVS | Novartis AG | -0.75% | 82.95 | 0.2% | $156.40m | |
| CRVS | Corvus Pharmaceuticals, Inc. | -3.27% | 6.80 | 0.7% | $140.27m | |
| GSK | GlaxoSmithKline Plc | -2.44% | 38.38 | 0.2% | $135.32m | |
| RGEN | Repligen Corp. | -0.29% | 323.26 | 6.8% | $123.14m | |
| SNY | Sanofi | -1.60% | 47.94 | 0.2% | $122.20m | |
| RPRX | Royalty Pharma Plc | -0.08% | 37.10 | 0.1% | $121.13m | |
| VTRS | Viatris, Inc. | 0.30% | 13.38 | 0.0% | $107.54m | |
| NVO | Novo Nordisk A/S | -1.36% | 100.71 | 0.1% | $101.76m |
Company Profile
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.